

Diabetic Retinopathy Guideline Committee Meeting 10

Date:24th March 2023Location:Virtual Meeting via ZoomMinutes:Final

Committee members present:

Mike Burdon (Chair)	Present for all items
John Anderson	Present for all items
Amandeep Bedi	Present for all items
Philip Burgess	Present for all items
Julie Davey	Present for all items
Christiana Dinah	Present for all items
Noemi Lois	Present for all items
Louis Savage	Present for all items
Diva Shah	Present for all items
Lloyd Thomas	Present for all items
Bernadette Warren	Present for all items

In attendance:		
Astrid Aregui	Senior Medical Editor, NICE	Present for all items
Jacqueline Durkin	Administrator, Guideline Development Team	Present for item 1
Becky Chadwick	Project Manager, Guideline Development Team	Present for all items
Kirsty Luckham	Technical Analyst (Health Economics)	Present for all items
Yolanda Martinez	Technical Analyst, Guideline Development Team	Present for all items
Syed Mohiuddin	Technical Adviser (Health Economics)	Present for all items
Mark Simmonds	AVID Principal Investigator, Centre for Reviews and Dissemination, University of York	Present for items 1-2
Ahmed Yosef	Technical Analyst, Guideline Development Team	Present for all items

Apologies:	
Catrina Charlton	Guideline Commissioning Manager, NICE
Rosalind Creer	Committee Member
Nicola Cunliffe	Project Manager, Guideline Development Team
Becky Wei Luo	Committee Member
Hannah Tebbs	Technical Analyst (Health Economics)

Philip Williams

NICE Resource Impact Lead

1. Welcome and DOIs for the meeting

The Chair welcomed the committee members and attendees to the 10th meeting on Diabetic Retinopathy. The committee members and attendees introduced themselves. The Chair informed the Committee that apologies had been received, these are noted above.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Diabetic Retinopathy. The Chair asked everyone to verbally declare any new interests that are not listed in the registry. No new interests were declared.

2. Follow up presentation on revised results - laser and anti-VEGF for PDR (RQ5)

The Chair introduced Mark Simmonds (MS), who presented the revised results for laser and anti-VEGF for PDR RQ5.and led a discussion with the committee.

3. Treatments for non-PDR and PDR (RQ5)

- Evidence review
- Economic evidence

The Chair introduced Ahmed Yousef (AY) and Kirsty Luckham (KL) who presented the evidence for RQ5. The committee had the opportunity to give feedback and ask questions.

4. Discussion of evidence and recommendation drafting (RQ5)

The committee had a discussion of the evidence and recommendations were drafted for RQ5.

5. Treatments for DMO (RQ7)

- Evidence review
- Economic evidence

AY and KL presented the evidence for RQ7 and the committee had the opportunity to give feedback and ask questions. The committee had the opportunity to give feedback and ask questions.

6. Discussion of evidence and recommendation drafting (RQ7).

The committee had a discussion of the evidence and recommendations were drafted for RQ7.

7. AOB, summary and next steps

The Chair confirmed the next meeting date, next steps and thanked those present for their contributions. The meeting concluded.